MYCOPHENILIC ACID vs SIROLIMUS

Compare MYCOPHENILIC ACID (Mycophenolic Acid) and SIROLIMUS (sirolimus) — clinical data, side effects, and patient experiences.

MYCOPHENILIC ACID

Mycophenolic Acid · Immunosuppressant

How it works

12.1 Mechanism of Action Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore i...

Approved for

See full prescribing information

OralTablet

SIROLIMUS

sirolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimul...

Approved for

1.2

it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids

peak PRA level > 80%])

it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration ( 2.3 )

OralTablet

Quick Comparison

MYCOPHENILIC ACIDSIROLIMUS

Drug Class

Immunosuppressant

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MYCOPHENILIC ACID

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

Nausea

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Shortness of Breath

0.1-1%

SIROLIMUS

Drug Not Working

>10%

Fever

1-10%

Diarrhea

1-10%

Condition Worsened

0.1-1%

FDA Warnings

MYCOPHENILIC ACID

5 WARNINGS AND PRECAUTIONS New or Reactivated Viral Infections: Consider reducing immunosuppression
6 ) Serious GI Tract Complications (gastrointestinal bleeding, perforations and ulcers): Administer with caution to patients with active digestive system disease
1 Embryo-Fetal Toxicity Use of mycophenolic acid delayed-release tablets during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities, including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system
Females of reproductive potential must be aware of these risks and must be counseled regarding pregnancy prevention and planning

SIROLIMUS

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions ( 5
12 ) Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic Microangiopathy ( 5
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis
Many of these patients had evidence of infection at or near the time of death

Clinical Trial Data

No head-to-head clinical studies found for MYCOPHENILIC ACID vs SIROLIMUS.

MYCOPHENILIC ACID vs SIROLIMUS: What You Should Know

Key Differences

Both MYCOPHENILIC ACID and SIROLIMUS belong to the Immunosuppressant class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

MYCOPHENILIC ACID carries 4 FDA warnings. SIROLIMUS carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EVEROLIMUS vs SIROLIMUS→EVEROLIMUS vs MYCOPHENILIC ACID→CYCLOSPORINE OPHTHALMIC SOLUTION vs SIROLIMUS→CYCLOSPORINE vs SIROLIMUS→CYCLOSPORINE OPHTHALMIC SOLUTION vs MYCOPHENILIC ACID→CYCLOSPORINE vs MYCOPHENILIC ACID→

Loading comparison data...

MYCOPHENILIC ACID vs SIROLIMUS

Compare MYCOPHENILIC ACID (Mycophenolic Acid) and SIROLIMUS (sirolimus) — clinical data, side effects, and patient experiences.

MYCOPHENILIC ACID

Mycophenolic Acid · Immunosuppressant

How it works

12.1 Mechanism of Action Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore i...

Approved for

See full prescribing information

OralTablet

SIROLIMUS

sirolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimul...

Approved for

1.2

it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids

peak PRA level > 80%])

it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration ( 2.3 )

OralTablet

Quick Comparison

MYCOPHENILIC ACIDSIROLIMUS

Drug Class

Immunosuppressant

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MYCOPHENILIC ACID

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

Nausea

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Shortness of Breath

0.1-1%

SIROLIMUS

Drug Not Working

>10%

Fever

1-10%

Diarrhea

1-10%

Condition Worsened

0.1-1%

FDA Warnings

MYCOPHENILIC ACID

5 WARNINGS AND PRECAUTIONS New or Reactivated Viral Infections: Consider reducing immunosuppression
6 ) Serious GI Tract Complications (gastrointestinal bleeding, perforations and ulcers): Administer with caution to patients with active digestive system disease
1 Embryo-Fetal Toxicity Use of mycophenolic acid delayed-release tablets during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities, including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system
Females of reproductive potential must be aware of these risks and must be counseled regarding pregnancy prevention and planning

SIROLIMUS

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions ( 5
12 ) Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic Microangiopathy ( 5
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis
Many of these patients had evidence of infection at or near the time of death

Clinical Trial Data

No head-to-head clinical studies found for MYCOPHENILIC ACID vs SIROLIMUS.

MYCOPHENILIC ACID vs SIROLIMUS: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.